Chardan Capital Issues Positive Forecast for Palvella Therapeutics (NASDAQ:PVLA) Stock Price

Palvella Therapeutics (NASDAQ:PVLA) had its price objective increased by Chardan Capital from $210.00 to $240.00 in a research note published on Tuesday morning,Benzinga reports. Chardan Capital currently has a buy rating on the stock.

Several other analysts have also issued reports on the stock. Truist Financial set a $210.00 price target on shares of Palvella Therapeutics in a research report on Tuesday, February 24th. Stifel Nicolaus set a $250.00 target price on shares of Palvella Therapeutics in a report on Tuesday, February 24th. Mizuho increased their target price on Palvella Therapeutics from $205.00 to $250.00 and gave the stock an “outperform” rating in a research report on Wednesday, February 25th. BTIG Research raised their price target on Palvella Therapeutics from $192.00 to $215.00 and gave the stock a “buy” rating in a report on Wednesday, February 25th. Finally, HC Wainwright boosted their price objective on Palvella Therapeutics from $255.00 to $270.00 and gave the company a “buy” rating in a research note on Tuesday, March 24th. One investment analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Palvella Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $198.07.

Palvella Therapeutics Stock Up 12.6%

PVLA stock opened at $124.65 on Tuesday. The firm has a market cap of $1.48 billion, a PE ratio of -47.40 and a beta of -0.30. The business has a 50 day moving average of $105.27 and a 200-day moving average of $91.65. Palvella Therapeutics has a 12-month low of $18.23 and a 12-month high of $151.18.

Palvella Therapeutics (NASDAQ:PVLA) last posted its quarterly earnings data on Tuesday, March 31st. The company reported ($1.08) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.95) by ($0.13). On average, research analysts expect that Palvella Therapeutics will post -3.69 earnings per share for the current year.

Insider Activity

In other Palvella Therapeutics news, Director Elaine J. Heron acquired 2,400 shares of the business’s stock in a transaction dated Friday, February 27th. The stock was bought at an average price of $125.00 per share, with a total value of $300,000.00. Following the completion of the acquisition, the director owned 47,812 shares of the company’s stock, valued at $5,976,500. This trade represents a 5.28% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director George M. Jenkins purchased 4,000 shares of the business’s stock in a transaction on Friday, February 27th. The stock was bought at an average cost of $125.00 per share, with a total value of $500,000.00. Following the purchase, the director owned 187,171 shares in the company, valued at approximately $23,396,375. This represents a 2.18% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Corporate insiders own 20.50% of the company’s stock.

Institutional Investors Weigh In On Palvella Therapeutics

A number of large investors have recently added to or reduced their stakes in PVLA. Millennium Management LLC purchased a new position in shares of Palvella Therapeutics in the 1st quarter worth about $7,553,000. Goldman Sachs Group Inc. purchased a new position in shares of Palvella Therapeutics during the 1st quarter valued at about $533,000. Geode Capital Management LLC lifted its position in Palvella Therapeutics by 84.7% in the 2nd quarter. Geode Capital Management LLC now owns 173,986 shares of the company’s stock worth $3,923,000 after buying an additional 79,787 shares during the last quarter. JPMorgan Chase & Co. boosted its stake in Palvella Therapeutics by 108,066.7% in the second quarter. JPMorgan Chase & Co. now owns 3,245 shares of the company’s stock worth $73,000 after buying an additional 3,242 shares in the last quarter. Finally, Rhumbline Advisers purchased a new stake in Palvella Therapeutics in the second quarter worth approximately $224,000. Hedge funds and other institutional investors own 40.11% of the company’s stock.

Key Stories Impacting Palvella Therapeutics

Here are the key news stories impacting Palvella Therapeutics this week:

• Positive Sentiment: Phase 3 SELVA showed statistically significant benefit for QTORIN™ rapamycin and Palvella says an NDA submission is on track for H2 2026 — a clear near-term regulatory/commercial catalyst. Palvella Therapeutics Reports Full Year 2025 Financial Results and Provides Corporate Update
• Positive Sentiment: Palvella closed an oversubscribed $230M equity offering and reports pro forma cash of ~ $274M, reducing near-term financing risk and supporting planned U.S. launch readiness. Palvella Therapeutics Reports Full Year 2025 Financial Results and Provides Corporate Update
• Positive Sentiment: Chardan Capital raised its price target to $240 and reiterated a Buy rating, amplifying bullish analyst sentiment and likely contributing to today’s buying interest. Benzinga
• Neutral Sentiment: A peer‑reviewed publication in the Journal of Vascular Anomalies supports the clinical rationale for topical rapamycin in microcystic lymphatic malformations, reinforcing scientific credibility but not an immediate stock-moving event on its own. Palvella Therapeutics Announces Scientific Publication
• Negative Sentiment: Q4 results included an EPS miss (reported $(1.08) vs. consensus $(0.95)) and a larger full‑year net loss as R&D and G&A ramped; cash as-of-Dec‑31 was $58M (pro forma $274M after financing) — investors will watch burn and runway. Palvella Therapeutics: Q4 Earnings Snapshot

About Palvella Therapeutics

Palvella Therapeutics, Inc (NASDAQ: PVLA) is a clinical‐stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small‐molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil‐ and complement‐mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.

Palvella’s pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes.